Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Linerixibat PK in Healthy Adults
NCT05435170Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linerixibat in pruritus (2 arms), sponsored by GSK. Primary endpoints: Plasma linerixibat area under the concentration-time curve from time zero to the time of the last quantifiable concentration and Maximum observed plasma concentration of linerixibat. Started Aug 2022; status: completed.
02
Drugs
linerixibat
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT05435170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435170.